|Published||Report Code||Available Format||Pages|
Note: This report can also be updated as of date and delivered within 1-2 working days of purchase confirmation
This report includes the Estrogen Receptor-Positive (ER+) breast cancer pipeline analysis as of 2017, to estimate and analyze the emerging therapies and their progress status in different phases of development. The report also contains competitive analysis and extensive information on monotherapies, combination therapies, targets and mechanism of action, and drug origin with relevance to ER+ breast cancer.
ER+ Breast Cancer Pipeline Analysis
Note: In the pipeline analysis, inactive and discontinued products have been analyzed separately.